Zinc Finger C2HC Domain-Containing Protein 1B: A Potential Drug Target and Biomarker

Target Name: ZC2HC1B

NCBI ID: G153918

ZC2HC1B

Zinc Finger C2HC Domain-Containing Protein 1B: A Potential Drug Target and Biomarker

Introduction

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes, including gene regulation, DNA replication, and protein-protein interactions. Zinc finger domains (ZFDs) are a subclass of ZFPs that are Characterized by the presence of a nucleotide-binding oligomerization domain (NBO), which consists of a nucleotide-binding oligomerization interaction and a domain that can bind to specific DNA sequences. Zinc finger C2HC domain-containing protein 1B (ZC2HC1B) is a ZFPs that was identified as a potential drug target and biomarker.

In this article, we will provide an overview of ZC2HC1B, including its structure, function, and potential drug targeting opportunities. We will discuss the current research on ZC2HC1B and its potential as a drug target and biomarker, and highlight its potential clinical applications.

Structure and Function

ZC2HC1B is a 21-kDa protein that contains a ZFN and a C2HC domain. The ZFN is a nucleotide-binding oligomerization domain that consists of a nucleotide-binding oligomerization interaction and a ZNF2-like domain. domain that consists of a nucleotide-binding oligomerization interaction and a ZNF2-like domain. ZC2HC1B also contains a N-terminal alpha-helix, a C-terminal alpha-helix, and a terminal N-terminus.

ZC2HC1B functions as a transcription factor that regulates gene expression. It is highly expressed in various tissues, including brain, heart, and muscle. ZC2HC1B has been shown to play a role in the regulation of various gene expression pathways, including cell growth, differentiation, and inflammation.

Potential Drug Targeting

ZC2HC1B is a potential drug target due to its unique structure and function. The ZFN and C2HC domains provide multiple opportunities for drug targeting. The ZFN can be targeted by small molecules that bind to the nucleotide-binding oligomerization interaction. The C2HC domain can be targeted by small molecules that bind to the nucleotide-binding oligomerization interaction and the ZNF2-like domain.

In addition to its potential as a drug target, ZC2HC1B also has the potential as a biomarker. The ZC2HC1B gene has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By targeting ZC2HC1B, researchers may be able to develop new diagnostic tools and therapeutic approaches for these diseases.

Potential Clinical Applications

ZC2HC1B has the potential to be a therapeutic agent for a variety of diseases. Its unique structure and function make it an attractive target for small molecules that can modulate its activity.

In oncology, ZC2HC1B has been shown to be involved in the regulation of various gene expression pathways that are critical for cancer growth and progression. Therefore, small molecules that can target ZC2HC1B and modulate its activity may be useful for the development of new cancer therapies.

In neurodegenerative diseases, ZC2HC1B has been shown to play a role in the regulation of various gene expression pathways that are critical for neurodegeneration. Therefore, small molecules that can target ZC2HC1B and modulate its activity may be useful for the development of new neurodegenerative therapies.

In autoimmune diseases, ZC2HC1B has

Protein Name: Zinc Finger C2HC-type Containing 1B

The "ZC2HC1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZC2HC1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets